SCYNEXIS Income from Continuous Operations 2013-2025 | SCYX

SCYNEXIS income from continuous operations from 2013 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change

SCYNEXIS Income from Continuous Operations 2013-2025 | SCYX

SCYNEXIS income from continuous operations from 2013 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$68.7B
Zoetis (ZTS)$66.4B
Takeda Pharmaceutical (TAK)$46.6B
Daiichi Sankyo, - (DSNKY)$46.2B
BeOne Medicines - (ONC)$31.6B
Sandoz Group AG (SDZNY)$26.1B
Summit Therapeutics (SMMT)$19.1B
Merck (MKKGY)$16.9B
Shionogi (SGIOY)$15.4B
United Therapeutics (UTHR)$13.6B
Neurocrine Biosciences (NBIX)$12.8B
Orion OYJ (ORINY)$10.8B
IPSEN (IPSEY)$10.4B
Madrigal Pharmaceuticals (MDGL)$8B
Corcept Therapeutics (CORT)$7.8B
Grifols, S.A (GRFS)$7.3B
Stevanato Group S.p.A (STVN)$6.6B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$5.3B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.4B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.8B
NewAmsterdam Pharma (NAMS)$2.8B
Crinetics Pharmaceuticals (CRNX)$2.7B
Hypermarcas (HYPMY)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.2B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B